{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-000172","form_type":"8-K","ticker":"INBS","cik":"0001725430","company_name":"INTELLIGENT BIO SOLUTIONS INC.","filed_at":"2025-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.630608+00:00","generated_at":"2026-05-24T08:49:38.219820+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Intelligent Bio Solutions expects sixth U.S. patent for fingerprint drug testing technology","bullets":["Expected patent will protect lateral flow technology core to its drug screening system.","Patent strengthens IP portfolio as company plans U.S. market entry in 2025.","CEO Harry Simeonidis states protection is critical for scaling U.S. footprint.","Recent FDA 510(k) submission supports non-invasive sweat-based testing approach.","INBS provides non-invasive alternative to traditional drug screening methods."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-000172","json":"https://secwatch.observer/filing/0001641172-25-000172.json","markdown":"https://secwatch.observer/filing/0001641172-25-000172.md","text":"https://secwatch.observer/filing/0001641172-25-000172.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725430/000164117225000172/0001641172-25-000172-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725430/000164117225000172/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T08:49:38.219820+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}